首页> 外国专利> Composition for treatment of night sight problems(halos, comas and glare) after refractive surgery, intra ocular lens implant after lensectomy or intraocular implant in phakic patients comprising aceclidine employed at low concentrations

Composition for treatment of night sight problems(halos, comas and glare) after refractive surgery, intra ocular lens implant after lensectomy or intraocular implant in phakic patients comprising aceclidine employed at low concentrations

机译:包含屈光手术的屈光手术患者的屈光手术后,晶状体切除术后的人工晶状体植入物或人工眼内植入物治疗夜视问题的组合物(晕圈,昏迷和眩光)

摘要

After refractive surgery to reduce ametropy (i.e. myopia, astigmatism or hypermetropia) an average percentage of patients between 15.8% after PRK (Photo Refractive Keratectomy) and 33% after LASIK (Laser in situ Keratomileusis) shows a poor night sight due to the presence of halos, glare and coma. A comparable disorder is present in a percentage of patients that underwent lensectomy (cataract or refractive lensectomy) with intra ocular lens (IOL) implant and IOL implants in phakic patients to reduce ametropy. Thanks to the effect on pupillary kinetics, diluted low concentrations (from 0.002% to 0.040%) of Aceclidine were surprisingly found to effectively reduce and/or eliminate night sight problems for about 6 hours.
机译:进行屈光手术以减少屈光不正(即近视,散光或远视)后,由于存在以下原因,平均患者百分比在PRK(屈光性角膜切除术)后为15.8%至LASIK(原位角膜磨镶术)后为33%光晕,眩光和昏迷。有一定比例的晶状体切除术患者接受晶状体摘除术(白内障或屈光性晶状体摘除术)后,在有晶状体眼患者中,有一定比例的疾病存在,以减少屈光不正。由于对瞳孔动力学的影响,令人惊讶地发现稀释的低浓度乙酰氯丁啶(0.002%至0.040%)可有效减少和/或消除夜视问题约6小时。

著录项

  • 公开/公告号US2004106644A1

    专利类型

  • 公开/公告日2004-06-03

    原文格式PDF

  • 申请/专利权人 RANDAZZO ALESSANDRO;

    申请/专利号US20030473740

  • 发明设计人 ALESSANDRO RANDAZZO;

    申请日2003-10-02

  • 分类号A61K31/4745;

  • 国家 US

  • 入库时间 2022-08-21 23:19:23

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号